Skip to main content

Read more about our corporate brand here.

Search
Search
Reports

Healthcare Industry Trends

2024 Mid-Year Report
Raysa Bousleiman, Kale Frank, Alex Lennox-Miller, Jackie Spencer, Timot Lamarre

Key takeaways

Our Healthcare Investments & Exits Mid-Year Report for 2024 examines the impact of fundraising, investment and exit trends on the VC-backed healthcare ecosystem.

55

Biopharma companies have landed deals of $100M and above so far this year.

2024 is on track to set the record for deals of this size within the sector.

89%

of US VC funds with a healthcare focus have hit fundraising targets in the first half of 2024.

This level of success outstrips all prior years except 2022.

More than 1 in 4

US healthcare companies that closed a venture capital deal of at least $15M reported a flat or down round in 2024.

This marks the highest proportion of down rounds in recent history.

The data

For nearly 20 years, First Citizens Innovation Banking has tracked trends in healthcare venture funding. In our latest edition of the Healthcare Investments & Exits report, we leverage our proprietary data to explore trends and offer expert commentary around fundraising, investment, M&As and IPOs in the healthcare market, as well as sector analysis for healthtech, biopharma, medical devices and diagnostics. We find that, despite strong headwinds, fundraising has remained strong so far this year, with a focus on quality over quantity.

HEALTHCARE VALUATIONS

Valuations are under the microscope

The exuberance of 2021 has given way to an era of unprecedented scrutiny for valuations, with at least 28% of deals in the US reporting down or flat rounds — the highest level seen in recent history.

With many of the unicorns formed in 2020 and 2021 yet to come back to market to raise another round, we expect to see more valuation resets ahead.

Chart depicting healthcare valuation changes for Series A and beyond Note: The methodology for this analysis has changed from prior reports. Up rounds defined as deals where the pre-money valuation is higher than the prior deal’s post-money valuation. Only deals with a reported deal size are considered for this analysis. Source: PitchBook Data, Inc. and SVB proprietary data and analysis
Chart depicting VC dollars and deals by healthcare sectors from 2019 to 2024 Source: PitchBook Data Inc. and SVB proprietary data and analysis.
HEALTHCARE INVESTMENTS

Investors prioritize quality over quantity

Extended diligence timelines and more conservative deals are making investors more confident. That confidence is translating into continued steady investment growth in 2024.

This investment activity marks the strongest start to a year outside of the pandemic investment boom of 2021 and 2022, laying the foundation for a healthy private market.

BIOPHARMA DEALS

Mega deals dominate in biopharma

With 55 deals $100M and above in the first half of 2024, biopharma is on track for a record year.

The other healthcare subsectors appear to have settled into a new normal for large dealmaking after sustaining major drops from their 2021 peaks.

Chart depicting the growth or decline in number of mega-deals in 2024 compared to 2020 Note: Deals $100M and above are considered mega deals. Source: PitchBook Data, Inc. and SVB proprietary data and analysis

First Citizens Innovation Banking's Global Life Science and Healthcare Practice

Discover how First Citizens Innovation Banking supports healthcare innovators and investors.

More about the authors

Raysa Bousleiman

Raysa Bousleiman

Kale Frank

Kale Frank

Alex Lennox-Miller
Market Insights

Alex Lennox-Miller

Senior Researcher

Jackie Spencer

Jackie Spencer

Timot Lamarre

Timot Lamarre


Explore other First Citizens Innovation Banking Reports

The Future of Healthtech 2026 Reports
Read Report Report

The Future of Healthtech 2026

Nov 09, 2026

Megan Scheffel, Adam Tweedy, Dennis He, Matt Donne, Alex Lennox-Miller, Urbashee Paul, Josh Pherigo

The Future of Fintech 2026 Reports
Read Report Report

The Future of Fintech 2026

Oct 13, 2026

Nick Christian, Brian Foley, Julie Wagne, Sophie McNaught, Josh Pherigo, Eli Oftedal, Andrew Pardo

The Future of Climate Tech Reports
Read Report Report

The Future of Climate Tech

Apr 15, 2026

Jordan Kanis, Eli Oftedal, Josh Pherigo, Andrew Pardo


The views expressed in this report are solely those of the authors and do not necessarily reflect the views of First Citizens Innovation Banking or Counterpart.

All non-SVB named companies listed throughout this document are independent third parties and are not affiliated with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company.

This material, including without limitation to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable, but which has not been independently verified by us, and, as such, we do not represent the information is accurate or complete. The information should not be viewed as tax, accounting, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment, or to engage in any other transaction.

Back to top
You are now leaving First Citizens Innovation Banking

You will be directed to a different website or mobile app that has its own terms of use, visitor agreement, security and privacy policies. First Citizens Innovation Banking is not responsible for (and does not provide) any products, services or content at the third party site or app, except for the products and services that carry the First Citizens Innovation Banking name.